Abiomed's Impella 2.5 enters new US trial
This article was originally published in Clinica
Executive Summary
A new clinical trial of Abiomed's Impella 2.5 circulatory support system is set to begin in the US following conditional FDA approval of the study protocol. The Impella device, already approved in Canada and CE marked in the EU, is inserted into the left ventricle in a minimally-invasive procedure, and helps pump blood in heart failure patients.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.